A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Key Inclusion Criteria:
• Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Key Exclusion Criteria:
• Hypersensitivity to investigational medicinal product or to any of its excipients
Other protocol defined Inclusion/Exclusion criteria will apply
medicalinfo@vrtx.com001-617-341-6777
Shreveport, Louisiana 71101, United States
Chengdu, China
Allemagne, Germany
Leipzig, Germany
Kawasaki-shi, Japan
Toyoake-Shi, Japan
Derby, United Kingdom
Doncaster, United Kingdom
London, United Kingdom